L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

254 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-05

Study Completion Date

2024-12-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to compare 28 day mortality rates between septic shock patients with acute renal insufficiency treated via L-Carnitine (as an adjunct therapy) versus a similar group of patients not receiving L-Carnitine adjunct therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rapid Administration of Carnitine in sEpsis

NCT01665092

Septic Shock

COMPLETED PHASE2

L-Carnitine Administration in Early Sepsis

NCT01193777

Septic Shock

TERMINATED PHASE1

Acetyl-L-Carnitine in the Treatment of Septic Shock

NCT00592488

Septic Shock

COMPLETED PHASE1/PHASE2

Early Metabolic Resuscitation for Septic Shock

NCT03895853

Multiple Organ Failure Septic Shock Severe Sepsis

TERMINATED PHASE2

Dysfunctional Renin-Angiotensin System in Septic Shock

NCT06746753

Septic Shock

NOT_YET_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The secondary objectives of this study are:

A. First secondary objective of this study is to compare 10 day mortality rates of septic shock patients with renal insufficiency treated via L-Carnitine (as an adjunct therapy) for 56 days versus a patients not receiving L-Carnitine adjunct therapy

B. To compare study arms in terms of patient safety.

C. To compare study arms in terms of further clinical outcomes, with special emphasis on nephrological outcomes.

D. To study (and compare between arms) the kinetic curves of free and total serum carnitine. Renal replacement therapy rapidly depletes the body's carnitine levels. Tracking adequate carnitine levels is therefore important for the interpretation of study results.

E. To constitute a bio-bank in association with the study for future ancillary studies (e.g. kidney injury marker studies, carnitine-responders versus non-responders, and other exploratory studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Sepsis Shock, Septic Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

L-Carnitine group

Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.

Intervention: 56 days of weight-adjusted L-Carnitine treatment

Group Type EXPERIMENTAL

56 days of weight-adjusted L-Carnitine treatment

Intervention Type DRUG

Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.

Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.

Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes

For the next 46 days, patients will take oral doses of L-Carnitine as follows:

\< à 60kg : 2g/day \> 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization

Placebo then open group

Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).

Intervention: 10 days of intravenous placebo (isotonic saline)

Group Type PLACEBO_COMPARATOR

10 days of intravenous placebo (isotonic saline)

Intervention Type DRUG

Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).

Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

56 days of weight-adjusted L-Carnitine treatment

Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.

Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.

Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes

For the next 46 days, patients will take oral doses of L-Carnitine as follows:

\< à 60kg : 2g/day \> 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization

Intervention Type DRUG

10 days of intravenous placebo (isotonic saline)

Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).

Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • The emergency inclusion procedure was correctly applied according to French law (signature of consent form by a patient-designated trusted person or a family member, or a medical decision to proceed with patient inclusion if the latter two persons are unavailable) ---- OR ---- signature of the consent form by the patient

* The patient must be insured or beneficiary of a health insurance plan
* The patient is at least 18 years old
* The patient was admitted to an intensive care unit (participating in the study) for sepsis or septic shock and presented with acute renal failure requiring, at some point, the use of extra-renal purification.
* • The patient has sepsis or septic shock according to international criteria SEPSIS 3 (Singer et al, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) ; JAMA. 2016)
* The patient has acute renal insufficiency with an KDIGO score of 3
* The patient has started continuous renal replacement therapy (CRRT) or intermittent renal replacement therapy (IRRT) within the previous 72 hours, or will start RRT (CRRT or IRRT) within the next 72 hours.

Exclusion Criteria

* • The patient is participating in, or has participated in over the past three months, another interventional study that may interfere with the results or conclusions of this study

* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection, or is an adult under guardianship
* The patient is pregnant, parturient or breastfeeding
* The patient is susceptible to procreate and does not use methods of effective contraception (contraceptive hormonal ring, surgical contraception, contraceptive implant, contraceptive pill, male or female sheaths, skin patch, intrauterine contraceptive device)
* If the patient is unable to sign a consent form: the patient-designated trusted person or family member refuses to sign the consent form
* If the patient is unable to sign a consent form: It is impossible to correctly inform the patient-designated trusted person or family member
* The patient is able/apt to sign a consent form, but refuses to do so
* The patient is able/apt to sign a consent form, but cannot be correctly informed
* Septic shock without associated AKI
* Patients with a known allergy to L-Carnitine or other component of levocarnil oral solution or for injection
* Pre-existing chronic disease requiring dialysis
* The patient has stage 4 CKD with baseline DFG (CDK) if known \<30 ml
* History of seizures or epilepsy
* Chronic bowel disease or history of chronic diarrhoea
* Under treatment with sodium valproate

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No